Proton pump inhibitors 200 scholarly articles free access

Proton Pump Inhibitors
Andres Marin, MD
Protonpump.ppt

Gastrointestinal Drugs
Karen Ruffin RN, MSN Ed.
GastrointestinalDrugs.ppt

Pediatric Laproscopic Nissen Fundoplication
Lindsey Bendure
Fundoplication.ppt

Acid-Controlling Agents
Acid-Controlling Agents.ppt

Gastric Acid Modifiers
Frank F. Vincenzi
Gastric Acid Modifiers.ppt

Gastrointestinal Drugs
Patrick T. Ronaldson, Ph.D.
GastrointestingDrugs.ppt

Gastric Secretion and Function
Gastricsecretion.ppt

Swallowing Difficulty & Pain
Tim Farrell, MD, Tom Egan, MD
Swallowing Difficulty & Pain.ppt

Drugs that Affect the Gastrointestinal System
Pharmacology/GIDrugs.ppt

Proton pump inhibitors
Proton pump inhibitors.ppt

Gastrointestinal Agents
Gastrointestinal Agents.ppt

Gastro Reflux
Debbie Tinus
Gastro Reflux.ppt

Drugs for Peptic Ulcer Disease
Gastro Reflux.ppt

Gastrointestinal Pharmacology
Gastrointestinal Pharmacology.ppt

Pathophysiology of GERD
Vicki Orzel RN/BSN
Pathophysiology of GERD.ppt

Gastroesophageal Reflux Disease (GERD)
Fantry_GERD_September7_2nd.ppt

Chronic Cough -Evaluation and Treatment
Bill Mariencheck
Chronic Cough Treatment.ppt

Pharmacology in Rehabilitation Gastrointestinal Drugs
Mary Worthington, Pharm.D.
Gastrointestinal Drugs.ppt
200 scholarly published articles free access

1. Bravo 48-hour Wireless pH Monitoring in Patients With Non-cardiac Chest Pain. Objective Gastroesophageal Reflux Disease Parameters Predict the Responses to Proton Pump Inhibitors.
2. Clinical manifestations and role of proton pump inhibitors in the management of laryngopharyngeal reflux.
3. Influence of proton pump inhibitors on dexamethasone-induced gastric mucosal damage in rats.
4. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study.
5. The favourable effect of Helicobacter pylori eradication therapy in patients with recurrent angina-like chest pain and non-responsive to proton pump inhibitors - a preliminary study.
6. Effects of proton pump inhibitors and h2 receptor antagonists on the ileum motility.
7. Are proton pump inhibitors a new antidiabetic drug? A cross sectional study.
8. Do Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Really Have No Effect on the Gastric Emptying Rate?: Author's Reply.
9. Do histamine-2 receptor antagonists and proton pump inhibitors really have no effect on the gastric emptying rate?
10. Proton-pump inhibitors: the devil or the savior for patients undergoing percutaneous coronary intervention?
11. Impact of pharmacotherapeutic warnings on the prescription of clopidogrel and proton pump inhibitors in hospitalised patients.
12. Effects of proton pump inhibitors in asthmatics with gastroesophageal reflux disease.
13. Are proton pump inhibitors effective in asthmatics with gastroesophageal reflux disease?.
14. In vitro evaluation of phototoxic properties of proton pump inhibitors, H2-receptor antagonists and statins.
15. The Safety and Efficiency of Proton Pump Inhibitors during Pregnancy and Conception.
16. The value of branded proton pump inhibitors: formulary considerations.
17. Proton pump inhibitors--uncommon adverse effects.
18. Premature discard of proton pump inhibitors: possible osteoporosis vs enhanced gastrointestinal bleed, adenocarcinoma efficacy.
19. Effects of Histamine-2 Receptor Antagonists and Proton Pump Inhibitors on the Rate of Gastric Emptying: A Crossover Study Using a Continuous Real-Time C Breath Test BreathID System.
20. Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention.
21. Proton pump inhibitors inhibit metformin uptake by organic cation transporters OCTs.
22. Proton-pump inhibitors for the treatment of functional dyspepsia.
23. Coadministration of clopidogrel and proton pump inhibitors.
24. Clinical significance of interactions between clopidogrel and proton pump inhibitors.
25. Clinical evidence of interaction between clopidogrel and proton pump inhibitors.
26. Which is the best choice for gastroesophageal disorders: Melatonin or proton pump inhibitors?
27. Role of proton pump inhibitors in the management of peptic ulcer bleeding.
28. Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence.
29. Balancing the risks and benefits of proton pump inhibitors.
30. Proton Pump Inhibitors in the Management of Tachypnoea following Panproctocolectomy: A Case of High Output Ileostomy.
31. False elevation of chromogranin A due to proton pump inhibitors.
32. Proton pump inhibitors in rheumatic diseases: clinical practice, drug interactions, bone fractures and risk of infections.
33. The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis.
34. Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits.
35. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
36. Proton pump inhibitors and infection risk.
37. Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent GHOST investigators.
38. Clinical usefulness of limited sampling strategies for estimating AUC of proton pump inhibitors.
39. Security of proton pump inhibitors.
40. Cost-utility of aspirin and proton pump inhibitors for primary prevention.
41. Clopidogrel--proton pump inhibitors drug interaction: implications to clinical practice.
42. Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome.
43. CYP2C19 genotype and proton pump inhibitors in clopidogrel-treated patients: does it take two to tango?
44. Comparative study of proton pump inhibitors on dexamethasone plus pylorus ligation induced ulcer model in rats.
45. Oral proton-pump inhibitors and step-down therapy for nonulcer dyspepsia: is this the right approach?
46. A clinical guide to using intravenous proton-pump inhibitors in reflux and peptic ulcers.
47. The safety of proton pump inhibitors and clopidogrel in patients after stroke.
48. The potential interaction between clopidogrel and proton pump inhibitors: a systematic review.
49. Drug Class Review: Proton Pump Inhibitors: Final Report Update 5 Internet.
50. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.
51. Platelet activity associated with concomitant use of clopidogrel and proton pump inhibitors in children with cardiovascular disease.
52. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects.
53. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.
54. Meniere's disease and the use of proton pump inhibitors.
55. Pattern of intravenous proton pump inhibitors use in ICU and Non-ICU setting: a prospective observational study.
56. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.
57. Letter by Potter and Le Lorier regarding article, "Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome".
58. Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea.
59. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study.
60. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study.
61. Do proton pump inhibitors decrease calcium absorption?
62. Proton pump inhibitors, fracture risk and selection bias: three studies, same database, two answers.
63. High-dose vs low-dose proton pump inhibitors for upper gastrointestinal bleeding: a meta-analysis.
64. Drug Class Review on Proton Pump Inhibitors: Final Report Internet.
65. Proton pump inhibitors without prescription.
66. Safety of the long-term use of proton pump inhibitors.
67. Study of cross-reactivity between proton pump inhibitors.
68. Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy.
69. Proton pump inhibitors for prophylaxis of nosocomial upper gastrointestinal tract bleeding: effect of standardized guidelines on prescribing practice.
70. Proton pump inhibitors and risk for recurrent Clostridium difficile infection.
71. High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials.
72. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program.
73. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.
74. Proton pump inhibitors do not cause stomach cancer.
75. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.
76. Inappropriate utilization of intravenous proton pump inhibitors in hospital practice--a prospective study of the extent of the problem and predictive factors.
77. Medications NSAIDs, statins, proton pump inhibitors and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
78. Proton pump inhibitors and non-prescription.
79. Clopidogrel and proton pump inhibitors: a new drug interaction?
80. Association Between Use of Proton Pump Inhibitors and a Clostridium difficile-Associated Disease Outbreak: Case-Control Study.
81. The interaction between clopidogrel and proton pump inhibitors PPI: is there any clinical relevance?
82. Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases.
83. Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin.
84. Controversy regarding the concomitant use of clopidogrel and proton pump inhibitors PPI.
85. Safety and effectiveness of combining clopidogrel and proton pump inhibitors.
86. Clinical trial update II: TRITON-TIMI 38 provides reassurance on concomitant use of proton pump inhibitors and thienopyridines.
87. Proton pump inhibitors and pain.
88. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome.
89. Proton pump inhibitors and clopidogrel: putting the interaction in perspective.
90. Effect of proton pump inhibitors and H2 antagonists on the stomach wall in 99mTc-sestamibi cardiac imaging.
91. Proton pump inhibitors should not be sold without prescription.
92. Impact of compliance with proton pump inhibitors on NSAID treatment.
93. Management of reflux symptoms with over-the-counter proton pump inhibitors: issues and proposed guidelines.
94. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA Proton Pump Inhibitors And Clopidogrel Association prospective randomized study.
95. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications.
96. Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection.
97. Hypomagnesaemia due to use of proton pump inhibitors--a review.
98. Administration of proton pump inhibitors in patients requiring enteral nutrition.
99. Interaction between clopidogrel and proton pump inhibitors.
100. Interaction between clopidogrel and proton pump inhibitors.
101. Proton pump inhibitors exert anti-allergic effects by reducing TCTP secretion.
102. Endoscopic submucosal dissection in the era of proton pump inhibitors.
103. Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002.
104. Proton pump inhibitors and clopidogrel - hazardous drug interaction or hazardous interpretation of data?
105. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study.
106. The drug-drug interaction between proton pump inhibitors and clopidogrel.
107. Proton pump inhibitors and osteoporosis-related fractures.
108. Nine cases of omeprazole allergy: cross-reactivity between proton pump inhibitors.
109. Does treatment with proton pump inhibitors for gastroesophageal reflux disease GERD improve asthma symptoms in children with asthma and GERD? A systematic review.
110. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
111. Prevalence of bile reflux in gastroesophageal reflux disease patients not responsive to proton pump inhibitors.
112. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors?
113. Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors.
114. Incremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis linked to a case-control study.
115. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.
116. Intravenous proton pump inhibitors prior to endoscopy in suspected upper gastrointestinal bleeding.
117. Pharmacology of proton pump inhibitors.
118. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials.
119. Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease.
120. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors.
121. Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors.
122. Management of laryngopharyngeal reflux with proton pump inhibitors.
123. Use of proton pump inhibitors and risk of osteoporosis-related fractures.
124. Proton pump inhibitors: balancing the benefits and potential fracture risks.
125. Spectrophotometric determination of certain benzimidazole proton pump inhibitors.
126. The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost-effectiveness analysis.
127. Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors.
128. Proton pump inhibitors in cirrhosis: tradition or evidence based practice?
129. Allergy to proton pump inhibitors: diagnosis and assessment of cross-reactivity.
130. Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors?
131. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease.
132. Proton pump inhibitors and gastritis.
133. When proton pump inhibitors fail.
134. Assessing the use of proton pump inhibitors in an internal medicine department.
135. Gastric juice for the diagnosis of H pylori infection in patients on proton pump inhibitors.
136. Proton pump inhibitors and an emerging epidemic of gastric fundic gland polyposis.
137. Co-prescribing of proton pump inhibitors among chronic users of NSAIDs in the UK.
138. Effect of CYP2C19*2 and
139. 17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.
140. Anti-inflammatory and anti-oxidative properties of proton pump inhibitors.
141. Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors.
142. Overprescribing proton pump inhibitors.
143. Dosing of proton pump inhibitors in a private hospital in Hong Kong.
144. Proton pump inhibitors are not antacids!
145. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
146. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
147. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors - a follow-up study of intraluminal-impedance guided therapy.
148. Long-term use of proton pump inhibitors does not affect the frequency, growth, or histologic characteristics of colon adenomas.
149. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
150. Probiotics and diarrhea: No proton pump inhibitors?
151. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'.
152. Proton pump inhibitors and gastric neoplasia.
153. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea?
154. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species.
155. Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?
156. Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study.
157. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study.
158. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis.
159. Predictors of inappropriate utilization of intravenous proton pump inhibitors.
160. Proton pump inhibitors in general medicine. Comparison of routine practices with marketing authorization indications.
161. Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease.
162. Inappropriate prescribing of proton pump inhibitors in primary care.
163. Metformin and vitamin B12 deficiency: the role of H2 receptor antagonists and proton pump inhibitors.
164. Systematic review: Rebound acid hypersecretion after therapy with proton pump inhibitors.
165. The chemically elegant proton pump inhibitors.
166. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism.
167. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study.
168. A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study.
169. Proton pump inhibitors and the risk of Clostridium difficile-associated disease: further evidence from the community.
170. Experimental model in the qualitative and quantitative assessment of non-Helicobacter gastric microflora under proton pump inhibitors action.
171. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial.
172. Systematic review: proton pump inhibitors PPIs for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
173. Proton pump inhibitors and gastric neoplasia.
174. Use of proton pump inhibitors during pregnancy and breastfeeding.
175. Mechanism of actions and clinical applications of proton pump inhibitors.
176. Persistence and adherence to proton pump inhibitors in daily clinical practice.
177. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources.
178. Effect of a therapeutic maximum allowable cost MAC program on the cost and utilization of proton pump inhibitors in an employer-sponsored drug plan in Canada.
179. Co-prescription of alginate based formulations & proton pump inhibitors PPIs in gastro-oesophageal reflux disease: time for rethink?
180. Gastroesophageal reflux disease and asthma: the role of proton pump inhibitors.
181. Synergistic interaction between proton pump inhibitors and resistance modifiers: promoting effects of antibiotics and plasmid curing.
182. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
183. Clinical use of proton pump inhibitors in gastrointestinal diseases.
184. Despite high satisfaction, majority of gastro-oesophageal reflux disease patients continue to use proton pump inhibitors after antireflux surgery.
185. The power of pharmacological sciences: the example of proton pump inhibitors.
186. A 30-month evaluation of the effects on the cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan.
187. Proton pump inhibitors match surgery in gastroesophageal reflux.
188. Review article: proton pump inhibitors and bacterial overgrowth.
189. Does eradication of Helicobacter pylori infection reduce hypergastrinema during long term therapy with proton pump inhibitors?
190. Proton pump inhibitors reduce the bioavailability of dietary vitamin C.
191. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.
192. Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients.
193. Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients.
194. Proton pump inhibitors and upper gastrointestinal bleeding.
195. Proton pump inhibitors in paediatrics.
196. Hypergastrinaemia in patients infected with Helicobacter pylori treated with proton pump inhibitors.
197. Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness.
198. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study.
199. Systematic review: Is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease?
200. Classification of dyspepsia and response to treatment with proton-pump inhibitors.
201. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs.